Lipoprotein Metabolism and Transport

Lipoproteins are the essential cargo ships of your bloodstream, transporting water-insoluble lipids to and from tissues. Understanding their distinct roles and metabolic pathways is foundational to clinical reasoning about atherosclerosis, cardiovascular disease, and common metabolic disorders like hypercholesterolemia. For the MCAT and your medical career, mastering this system provides a direct link between biochemistry, physiology, and patient care.

The Structure and Function of Lipoproteins

At their core, lipoproteins are spherical complexes that solubilize hydrophobic lipids for transport in the aqueous blood plasma. Every lipoprotein particle shares a common general structure. The outer shell is a monolayer of amphipathic phospholipids and free cholesterol, with their hydrophilic heads facing the blood. Embedded in this shell are specific proteins called apolipoproteins (or apoproteins), which act as structural components, enzyme cofactors, and ligands for cellular receptors. The inner core contains the hydrophobic cargo: triglycerides and cholesteryl esters.

The different lipoprotein classes—chylomicrons, VLDL, LDL, and HDL—are distinguished by their density, size, and, most importantly, their predominant apolipoproteins and lipid cargo. Density is inversely related to size; chylomicrons, which are the largest and most triglyceride-rich, are the least dense, while HDL, which is small and protein-rich, is the most dense. This structural understanding is key to predicting their behavior in the metabolic pathways.

The Exogenous Pathway: Dietary Fat Transport via Chylomicrons

This pathway handles lipids from your diet. In the intestinal enterocyte, absorbed dietary triglycerides and cholesterol are packaged into massive chylomicrons. Their primary structural apolipoprotein is apoB-48. Once secreted into the lymphatic system and then the bloodstream, chylomicrons acquire apoC-II and apoE from circulating HDL.

The critical event in the capillary beds of adipose and muscle tissue is lipolysis. Here, apoC-II on the chylomicron activates the endothelial enzyme lipoprotein lipase (LPL). LPL hydrolyzes the core triglycerides into free fatty acids and glycerol, which are taken up by the tissue for storage or energy. As the chylomicron loses triglycerides, it shrinks, becoming a chylomicron remnant. This remnant, still rich in dietary cholesterol and carrying apoE, is rapidly cleared by the liver. Hepatic receptors bind apoE, mediating endocytosis of the remnant. MCAT Focus: A deficiency in LPL or its cofactor apoC-II leads to severe hypertriglyceridemia and postprandial lipemia, a classic biochemical concept.

The Endogenous Pathway: VLDL, IDL, and LDL Metabolism

While chylomicrons transport dietary (exogenous) fat, the liver synthesizes very-low-density lipoprotein (VLDL) to transport endogenous triglycerides. The liver packages triglycerides and cholesterol into VLDL, which contains apoB-100 as its essential structural protein. Like chylomicrons, nascent VLDL picks up apoC-II and apoE in circulation and travels to peripheral capillaries.

LPL, again activated by apoC-II, hydrolyzes VLDL triglycerides. As VLDL loses its triglyceride core, it first becomes an intermediate-density lipoprotein (IDL). Some IDL particles are quickly taken up by the liver via apoE receptors. The remainder remains in circulation, where hepatic hepatic lipase (HL) further modifies it, removing most remaining triglycerides. This process transforms IDL into low-density lipoprotein (LDL), the final product of the VLDL cascade. LDL retains only apoB-100 and is now cholesterol-rich, containing the majority of plasma cholesterol.

LDL Receptor-Mediated Endocytosis and Cholesterol Homeostasis

The LDL receptor is the master regulator of plasma LDL-cholesterol levels. This cell-surface receptor specifically binds apoB-100 on LDL particles (and apoE on other remnants). Upon binding, the receptor-LDL complex is internalized via clathrin-mediated endocytosis into an endosome. The endosome's acidic environment causes the receptor to release LDL. The receptor recycles back to the membrane, while the LDL particle is delivered to a lysosome for degradation. Lysosomal enzymes break down the lipoprotein, releasing free cholesterol into the cell cytoplasm for membrane synthesis or steroid hormone production.

This process is exquisitely regulated. High intracellular cholesterol levels downregulate the transcription of the gene for the LDL receptor and the key cholesterol synthesis enzyme, HMG-CoA reductase. This feedback inhibition prevents cholesterol overaccumulation. MCAT & Clinical Focus: Familial Hypercholesterolemia results from mutations in the LDL receptor gene, leading to massively elevated plasma LDL, premature atherosclerosis, and tendon xanthomas. This is a classic link between molecular defect and clinical phenotype.

HDL and Reverse Cholesterol Transport

High-density lipoprotein (HDL) functions very differently from the other lipoproteins. Its primary role is reverse cholesterol transport—picking up excess cholesterol from peripheral tissues and arterial walls and returning it to the liver for excretion. Nascent, disk-shaped HDL is secreted by the liver and intestine. Its major apolipoproteins are apoA-I and apoA-II.

The key enzyme here is lecithin-cholesterol acyltransferase (LCAT), activated by apoA-I on HDL. LCAT esterifies free cholesterol picked up from tissues into cholesteryl esters, which move into the hydrophobic core of HDL. This maturation process converts nascent HDL into spherical, mature HDL. HDL cholesterol can be delivered to the liver via two main routes: 1) direct uptake via the scavenger receptor class B type I (SR-BI), or 2) transfer of its cholesteryl esters to apoB-containing lipoproteins (like VLDL and LDL) in exchange for triglycerides, via the cholesteryl ester transfer protein (CETP). These triglycerides are then hydrolyzed by hepatic lipase, regenerating small HDL particles. The cholesterol on the transferred LDL is ultimately cleared by the liver via the LDL receptor pathway.

Common Pitfalls

1. Confusing the source and cargo of chylomicrons vs. VLDL.

• Pitfall: Thinking both transport dietary fat.
• Correction: Chylomicrons are exogenous from the intestine (diet). VLDL is endogenous from the liver (synthesized fat). On the MCAT, "postprandial" (after a meal) cues point to chylomicrons.

2. Misidentifying the apolipoprotein functions.

• Pitfall: Believing apoB-48 is in VLDL or that apoC-II is an inhibitor.
• Correction: Use a mnemonic: B-48 from the intestine (chylomicrons), B-100 from the Liver (VLDL/LDL). C-II "Clears" triglycerides by activating LPL. A-I Activates LCAT. E is for "Everything" remnant clearance.

3. Equating HDL-C levels directly with reverse cholesterol transport efficiency.

• Pitfall: Assuming a high HDL-cholesterol (HDL-C) measurement always means better cholesterol clearance.
• Correction: HDL function (flux) is more important than static concentration. Some genetic variants or conditions (e.g., metabolic syndrome) can lead to dysfunctional HDL that is poor at reverse transport, despite normal or high levels. MCAT questions may test the concept of reverse transport separately from the lab value.

4. Overlooking the central role of the LDL receptor beyond just LDL.

• Pitfall: Thinking the LDL receptor only clears LDL particles.
• Correction: It is crucial for clearing IDL (via apoE) as well. Its genetic absence (FH) leads to high levels of both LDL and its precursors.

Summary

• Lipoproteins are triglyceride and cholesterol transporters, classified by density: Chylomicrons (least dense) > VLDL > IDL > LDL > HDL (most dense).
• The exogenous pathway uses chylomicrons (apoB-48) to carry dietary fat; LPL (activated by apoC-II) unloads triglycerides, and the liver clears remnants via apoE.
• The endogenous pathway starts with hepatic VLDL (apoB-100), which is processed by LPL and hepatic lipase into IDL and finally LDL, the major cholesterol-delivery particle.
• Cellular cholesterol uptake is regulated by LDL receptor-mediated endocytosis, a feedback-controlled process whose failure causes Familial Hypercholesterolemia.
• HDL (apoA-I) mediates reverse cholesterol transport, using LCAT to esterify tissue cholesterol and returning it to the liver directly or via CETP exchange, protecting against atherosclerosis.